NCT03843515View on ClinicalTrials.gov

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

PHASE1UnknownINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

November 30, 2021

Study Completion Date

August 31, 2022

Conditions

Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Nivolumab

Neoadjuvant nivolumab flat dose 400mg

Trial Locations (1)

1081 HV

VU University medical center, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Amsterdam UMC, location VUmc

OTHER

NCT03843515 - Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction | Biotech Hunter | Biotech Hunter